• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605).
  

PubMed=26095605; DOI=10.1016/j.stemcr.2015.05.010; PMCID=PMC4618251
Cusulin C., Chesnelong C., Bose P., Bilenky M., Kopciuk K., Chan J.A.W., Cairncross J.G., Jones S.J.M., Marra M.A., Luchman H.A., Weiss S.
Precursor states of brain tumor initiating cell lines are predictive of survival in xenografts and associated with glioblastoma subtypes.
Stem Cell Reports 5:1-9(2015)

PubMed=26245525; DOI=10.1093/neuonc/nov143; PMCID=PMC4767234
Davis B., Shen Y.-Q., Poon C.C., Luchman H.A., Stechishin O.D.M., Pontifex C.S., Wu W., Kelly J.J.P., Blough M.D.
Terry Fox Research Institute Glioblastoma Consortium
Comparative genomic and genetic analysis of glioblastoma-derived brain tumor-initiating cells and their parent tumors.
Neuro-oncol. 18:350-360(2016)

PubMed=27006494; DOI=10.1158/1078-0432.CCR-15-1798
Lun X.-Q., Wells J.C., Grinshtein N., King J.C., Hao X.-G., Dang N.-H., Wang X.-L., Aman A., Uehling D., Datti A., Wrana J.L., Easaw J.C., Luchman H.A., Weiss S., Cairncross J.G., Kaplan D.R., Robbins S.M., Senger D.L.
Disulfiram when combined with copper enhances the therapeutic effects of temozolomide for the treatment of glioblastoma.
Clin. Cancer Res. 22:3860-3875(2016)

PubMed=30153289; DOI=10.1371/journal.pone.0202860; PMCID=PMC6112648
Yuan A.L., Ricks C.B., Bohm A.K., Lun X.-Q., Maxwell L., Safdar S., Bukhari S., Gerber A., Sayeed W., Bering E.A., Pedersen H., Chan J.A.W., Shen Y.-Q., Marra M.A., Kaplan D.R., Mason W.P., Goodman L.D., Ezhilarasan R., Kaufmann A.B., Cabral M., Robbins S.M., Senger D.L., Cahill D.P., Sulman E.P., Cairncross J.G., Blough M.D.
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts.
PLoS ONE 13:E0202860-E0202860(2018)